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Among kinases that support the survival and 
turnover of tumor cells, the serine/threonine protein kinase 
CK2 has been shown to be frequently overexpressed or 
hyperactivated in solid and hematological malignancies. 
Our previous work on T-cell acute lymphoblastic leukemia 
(T-ALL) showed that CK2 maintains leukemia cell 
viability by phosphorylating and thereby inactivating the 
tumor suppressor PTEN, which results in hyperactivation 
of PI3K/AKT signaling [1]. We also demonstrated the 
potential of using the clinical-grade CK2-specific chemical 
inhibitor, CX-4945 (Silmitasertib), against primary T-ALL 
cells [2]. We have now [3] extended these findings to the 
rare (<10% of all cases) form of T-ALL that derives from 
the transformation of thymocytes belonging to the γδ 
T-cell lineage [4].
γδ T cells develop in the thymus from progenitors 
common to the αβ T-cell lineage, and constitute a small 
population (1-5%) of the circulating T lymphocyte pool 
of healthy humans. In leukemia, malignant γδ T cells 
cause the γδ T-ALL subtype that presents with distinctive 
clinical features [4]. However, the molecular mechanisms 
that support γδ T-ALL homeostasis and progression 
remain poorly understood. 
In our most recent study, we identify CK2 as a novel 
determinant of γδ T-ALL cell survival [3]. Consistent with 
previous T-ALL data [1-2], CK2 promoted γδ T-ALL 
cell survival partly via AKT signaling, as demonstrated 
by the negative effects of CX-4945 on PTEN and AKT 
phosphorylation; the impact of the AKT inhibitor MK-
2206; and the partial rescue of CX-4945-induced apoptosis 
upon ectopic expression of a constitutively active AKT 
isoform [3]. Remarkably, however, primary γδ T-ALL 
cells were clearly more dependent on CK2 than αβ T-ALL 
cells, with significantly higher CK2 activity and sensitivity 
to CX-4945. Accordingly, CX-4945 treatment inhibited 
tumor progression and dissemination in a xenograft 
model of γδ T-ALL, thus supporting CK2 inhibition as a 
therapeutic approach in γδ T-ALL.
Interestingly, our study also revealed an 
unanticipated role for CK2 in controlling the survival 
of normal γδ thymocytes [3], which contrasted with our 
previous findings on healthy αβ thymocytes [1]. Thus, γδ 
thymocytes presented increased CK2 activity (which was 
further upregulated upon TCR stimulation) than their αβ 
counterparts; and, unlike these, were highly susceptible to 
CX-4945-induced apoptosis. This suggests that a possible 
unwanted side effect of CX-4945 treatment in cancer 
patients may be the depletion of healthy γδ T cells that 
provide anti-tumor immune surveillance [5].
Of note, studies in mice have suggested that CK2 is 
also involved in the suppressive function of CD4+ Foxp3+ 
regulatory T cells against allergy-promoting Th2 cells 
[6]; and in naïve CD4+ T cell differentiation into Th2 or 
Th17 cells [7]. Thus, CK2 inhibition may impact on other 
protective (against infection) or pathogenic (allergic or 
auto-inflammatory) immune responses.
The mechanisms of regulation of CK2 activity 
remain largely unknown, with very few studies 
demonstrating the modulation of CK2 activity by 
extracellular factors. Our results show that CK2 activity 
can be enhanced by TCR and CD27 (co)stimulation in γδ 
T cells [3]. In a different study, we have also demonstrated 
that IL-7/IL-7R stimulation upregulates CK2 activity, 
which is required for maximal IL-7R-triggered JAK1/
STAT5 and AKT signaling, and consequent pro-leukemia 
effects, in T-ALL cells [8]. Therefore, major molecular 
cues in T cell development may converge in increasing 
(by yet unclear mechanisms) CK2 activity in healthy and 
malignant thymocytes. As such, our studies collectively 
support the use of CK2 inhibitors (e.g. CX-4945) as 
putative therapy for both αβ and γδ T-ALL.
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